65,437 trials
Impaired Fasting Glucose · Prediabetes
Primary: Acute Insulin Response (AIRg) to Intravenous Glucose — 1866; 1752 pmol/1*min
Epilepsy
Primary: Percentage of Participants Wiith Reduction in Number of Seizures Greater Than or Equal to 50%, During the Last 4 Months of Treatment — 7.0; 2.4; 3.0 percentage of…
HIV Infections
Primary: Area Under the Curve of BUP/NLX With TPV/r (h*ng/mL) — 43.7 h*ng/mL
Breast Cancer · Cardiac Toxicity
Primary: Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment — 0 participants
HIV Infections
Primary: Buprenorphine Area Under the Curve With LPV/r (ng/mL*hr) — 46.2 (ng/mL)*hr
Polycystic Kidney, Autosomal Dominant · Polycystic Liver Disease · Hepatomegaly
Primary: Percent Change in Liver Volume — -5.0; 0.9 percent change — p=0.048
Cervical Strain
Primary: Pain
Lower Back Pain
Primary: Subject Rated Change Relief From Starting Backache of Pain on a 100-point Visual Analog Scale — 16.4; 15.5; 15.2 mm
HIV Infection · HIV Infections
Primary: Area Under the Curve (AUC) of BUP/NLX With Raltegravir (hr*ng/mL) — 56.0 hr*ng/mL
Diabetic Foot Ulcers · Foot Wounds
Primary: Bates-Jensen Wound Assessment Score - Modified (BWAT-m) — 15.8; 13.8 units on a scale — p==0.208
Lung Cancer
Primary: Survival Rate at 6-months Chemotherapy-progression-free (CP-free) — 55 percentage of participants
Psoriasis
Primary: Number of Participants Achieving a Greater Than or Equal to 75 Percentage Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 12…
Japanese Encephalitis
Primary: Geometric Mean Titer (GMT) for Anti-JEV Neutralizing Antibody — 160.8; 188.2; 168.4 titers
Vaginal Prolapse
Primary: Count of Patients With at Least One Adverse Event Related to Any AMS Prolapse Device — 194 participants
Major Depressive Disorder · Depression
Primary: Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment. — -12.7; -11.7 units on a scale — p=0.349